Potential Mechanisms Underlying Anxiety and Depression in Parkinson's Disease: Consequences of L-Dopa Treatment

Neuroscience and Biobehavioral Reviews- United Kingdom

doi 10.1016/j.neubiorev.2010.06.007

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Selegiline (L-Deprenyl) and L-Dopa Treatment of Parkinson's Disease: A Double-Blind Trial.

Internal Medicine
Internal MedicineMedicine
1994English

The Role of GRK6 in Animal Models of Parkinson's Disease and L-Dopa Treatment

Scientific Reports
Multidisciplinary
2012English

L-Dopa for Parkinson's Disease - A Bittersweet Pill

European Journal of Neuroscience
Neuroscience
2018English

Anxiety and Parkinson's Disease

Journal of Neuropsychiatry and Clinical Neurosciences
MedicinePsychiatryMental HealthNeurology
1996English

Neuroactive Steroids and Neurosteroids in the Mechanisms of Depression and Anxiety Disorders: Potential Therapeutic Opportunities in Depression and Anxiety Disorders

Farmacja Polska
2018English

Depression in Parkinson's Disease

Nevrologiya, Neiropsikhiatriya, Psikhosomatika
PsychiatryClinical PsychologyMental HealthNeurology
2010English

Moclobemide and Selegeline in the Treatment of Depression in Parkinson's Disease

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1997English

Depression and Anxiety in Cardiovascular Disease

Kardiologia Polska
Cardiovascular MedicineCardiology
2016English

Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety

Journal of Neuroscience
Neuroscience
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy